导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.05% | 1451/4773 |
| 近一周 | -2.65% | 2760/5462 |
| 近一月 | -5.27% | 3140/5421 |
| 近一季 | -9.25% | 3150/5209 |
| 近半年 | -6.60% | 3109/4920 |
| 近一年 | 8.03% | 1229/4366 |
| 近两年 | 75.73% | 867/2954 |
| 近三年 | 38.42% | 762/2253 |
| 成立以来 | 39.95% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.04% 1087/4961 |
19.67% 1283/5312 |
- - |
- - |
| 2025 | 32.50% 1179/4813 |
2.16% 1451/3635 |
2.09% 1877/4076 |
25.90% 1372/4524 |
0.90% 1678/4813 |
| 2024 | 6.80% 1722/3463 |
-2.83% 1439/2808 |
-5.58% 1753/3014 |
16.84% 1338/3129 |
-0.38% 1397/3463 |
| 2023 | -6.66% 867/2656 |
7.85% 519/2280 |
-4.34% 1143/2385 |
-4.92% 1257/2515 |
-4.84% 1193/2655 |
| 2022 | -18.56% 726/2207 |
-14.19% 913/1919 |
3.62% 1122/2016 |
-10.88% 458/2113 |
2.78% 839/2208 |
| 2021 | 17.33% 236/1822 |
-1.52% 508/1255 |
10.03% 498/1330 |
4.52% 342/1466 |
3.60% 416/1822 |
| 2020 | - - |
- - |
- - |
- - |
3.25% 931/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 泰康中证500ETF VS. 长安沪深300非周期A(740101) |